Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Production of truncated MBD4 protein by frameshift mutation in DNA mismatch repair-deficient cells enhances 5-fluorouracil sensitivity that is independent of hMLH1 status.
Suzuki S, Iwaizumi M, Tseng-Rogenski S, Hamaya Y, Miyajima H, Kanaoka S, Sugimoto K, Carethers JM. Suzuki S, et al. Among authors: kanaoka s. Cancer Biol Ther. 2016 Jul 2;17(7):760-8. doi: 10.1080/15384047.2016.1178430. Epub 2016 Apr 26. Cancer Biol Ther. 2016. PMID: 27115207 Free PMC article.
Cyclooxygenase-2 and tumor biology.
Kanaoka S, Takai T, Yoshida K. Kanaoka S, et al. Adv Clin Chem. 2007;43:59-78. Adv Clin Chem. 2007. PMID: 17249380 Review.
Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma.
Osawa S, Furuta T, Sugimoto K, Kosugi T, Terai T, Yamade M, Takayanagi Y, Nishino M, Hamaya Y, Kodaira C, Yamada T, Iwaizumi M, Takagaki K, Yoshida K, Kanaoka S, Ikuma M. Osawa S, et al. Among authors: kanaoka s. BMC Cancer. 2009 Nov 22;9:408. doi: 10.1186/1471-2407-9-408. BMC Cancer. 2009. PMID: 19930599 Free PMC article. Clinical Trial.
MBD4 frameshift mutation caused by DNA mismatch repair deficiency enhances cytotoxicity by trifluridine, an active antitumor agent of TAS-102, in colorectal cancer cells.
Suzuki S, Iwaizumi M, Yamada H, Sugiyama T, Hamaya Y, Furuta T, Kanaoka S, Sugimura H, Miyajima H, Osawa S, Carethers JM, Sugimoto K. Suzuki S, et al. Among authors: kanaoka s. Oncotarget. 2017 Nov 15;9(14):11477-11488. doi: 10.18632/oncotarget.22484. eCollection 2018 Feb 20. Oncotarget. 2017. PMID: 29545913 Free PMC article.
65 results